MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- Sector Info (List of bse healthcare Stocks)
- List of BSE Healthcare Stocks
List of BSE Healthcare
Stocks 
Here are the latest stock price details of the stocks in the BSE Healthcare. For more detailed updates, check the latest BSE Healthcare stock results and see the latest BSE Healthcare long term chart.
JUST IN: Limited-Time Access to Full Transcript of Our Urgent Broadcast on India's Revival
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | MORE INFO |
|---|---|---|---|---|
| AARTI DRUGS | 701.60 -0.33% | 701.85 -0.28% |
|
More Info
|
| ABBOTT INDIA | 14,962.95 0.14% | 14,964.85 0.30% |
|
More Info
|
| AJANTA PHARMA | 1,728.60 1.50% | 1,730.90 1.25% |
|
More Info
|
| ALEMBIC PHARMA | 1,000.60 2.94% | 1,001.20 2.94% |
|
More Info
|
| ALKEM LABORATORIES | 2,790.45 1.57% | 2,790.80 1.47% |
|
More Info
|
| APOLLO HOSPITALS | 3,060.20 2.32% | 3,061.00 2.25% |
|
More Info
|
| ASTER DM HEALTHCARE | 146.55 4.16% | 145.50 3.37% |
|
More Info
|
| ASTRAZENECA PHARMA | 3,456.35 -1.30% | 3,455.70 -1.41% |
|
More Info
|
| AUROBINDO PHARMA | 953.00 4.19% | 953.00 4.12% |
|
More Info
|
| BIOCON | 412.80 2.05% | 412.85 2.04% |
|
More Info
|
| BLISS GVS PHARMA | 96.20 0.05% | 96.05 0.21% |
|
More Info
|
| CADILA HEALTHCARE | 527.00 4.56% | 527.10 4.44% |
|
More Info
|
| CAPLIN POINT | 466.20 3.28% | Not Listed |
|
More Info
|
| CIPLA | 938.70 2.68% | 938.05 2.61% |
|
More Info
|
| DISHMAN CARBOGEN AMCIS | 123.55 6.33% | 123.70 6.55% |
|
More Info
|
| DIVIS LABORATORIES | 3,823.70 1.08% | 3,821.85 1.02% |
|
More Info
|
| DR. LAL PATHLABS | 2,917.80 -0.51% | 2,920.20 -0.54% |
|
More Info
|
| DR. REDDYS LAB | 4,893.00 1.04% | 4,893.25 0.98% |
|
More Info
|
| ERIS LIFESCIENCES | 587.60 -1.45% | 588.35 -1.18% |
|
More Info
|
| FDC | 312.50 0.24% | 312.70 0.37% |
|
More Info
|
| FERMENTA BIOTECH | 269.80 0.78% | Not Listed |
|
More Info
|
| FORTIS HEALTHCARE | 203.40 -1.33% | 203.65 -1.09% |
|
More Info
|
| GLENMARK PHARMA | 571.90 6.54% | 571.90 6.51% |
|
More Info
|
| GRANULES INDIA | 327.15 3.09% | 327.85 3.24% |
|
More Info
|
| GSK PHARMA | 1,469.60 0.41% | 1,470.20 0.32% |
|
More Info
|
| GUFIC BIOSCIENCE | 113.05 -0.44% | 112.85 -0.53% |
|
More Info
|
| HEALTHCARE GLOBAL ENTER. | 167.10 0.75% | 166.30 -0.03% |
|
More Info
|
| HESTER BIOSCIENCES | 2,349.45 16.71% | 2,343.85 16.38% |
|
More Info
|
| HIKAL. | 179.60 5.71% | 179.55 4.97% |
|
More Info
|
| INDOCO REMEDIES | 313.95 2.10% | 313.85 1.83% |
|
More Info
|
| INDRAPRASTHA MEDICAL | 55.45 -1.60% | 55.40 -1.42% |
|
More Info
|
| IOL CHEMICALS & PHARM. | 578.25 1.20% | 578.30 1.14% |
|
More Info
|
| IPCA LABS | 2,143.20 1.97% | 2,141.95 1.85% |
|
More Info
|
| J.B.CHEMICALS | 1,216.55 -1.01% | 1,221.10 -0.62% |
|
More Info
|
| JUBILANT PHARMOVA | 724.10 -0.30% | 722.00 -0.75% |
|
More Info
|
| LAURUS LABS | 446.15 2.25% | 446.50 2.29% |
|
More Info
|
| LINCOLN PHAR | 238.05 2.70% | 237.75 2.57% |
|
More Info
|
| LUPIN | 1,055.85 0.58% | 1,055.85 0.55% |
|
More Info
|
| MARKSANS PHARMA. | 54.70 1.58% | 54.70 1.58% |
|
More Info
|
| MEDICAMEN BI | 532.85 2.44% | Not Listed |
|
More Info
|
| MOREPEN LABS | 39.00 -3.58% | 39.00 -3.58% |
|
More Info
|
| NARAYANA HRUDAYALAYA | 401.50 -5.16% | 401.50 -5.28% |
|
More Info
|
| NATCO PHARMA | 921.85 1.12% | 922.20 1.27% |
|
More Info
|
| NECTAR LIFESCIENCE | 19.50 1.83% | 19.50 1.30% |
|
More Info
|
| NEULAND LABS | 2,427.70 0.79% | 2,425.40 0.41% |
|
More Info
|
| NIFTY 50 | Not Listed | 14,617.85 0.25% |
|
More Info
|
| NOVARTIS | 583.95 0.27% | Not Listed |
|
More Info
|
| PANACEA BIOTECH | 257.10 2.04% | 257.00 1.98% |
|
More Info
|
| PFIZER | 5,219.30 1.71% | 5,218.55 1.62% |
|
More Info
|
| PIRAMAL ENTERPRISES | 1,719.50 0.26% | 1,720.05 0.21% |
|
More Info
|
NSE prices: April 16, 2021 (Close)
BSE Healthcare Stocks Update
The S&P BSE HEALTHCARE Index was at 23,006.9 (up 1.9%). The index is up 9.2% over the last 30 days. And over the last 1 year, it has gained 55.9%.
Within the BSE Healthcare Index, the top gainers were HESTER BIOSCIENCES (up 16.7%) and VIVIMED LABS (up 15.5%). On the other hand, NARAYANA HRUDAYALAYA (down 5.2%) and MOREPEN LABS (down 3.6%) were among the top losers.
Meanwhile, the benchmark S&P BSE SENSEX was at 48,832.0 (up 0.1%).
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
- TRENDING ON EQUITYMASTER:
- Warren Buffett - The Value Investor
- Your Ultimate Guide to Penny Stock Investing
- How to Invest in Gold
- Basics of Value Investing
- Benjamin Graham
- The Best Bluechip Stocks to Buy
- How to Invest in Silver
- The Best Small-cap Stocks to Buy
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Best Stocks to Buy Today
- How to Use P/E for Successful Investing
- How to Find Undervalued Stocks
- Differences Between Trading and Investing
- SWOT Analysis for Stocks
- The Best Dividend Stocks to Buy
Today's Market
Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
Related Views on News
ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)
Feb 11, 2021 | Updated on Feb 11, 2021For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)
Feb 11, 2021 | Updated on Feb 11, 2021For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
LUPIN 2019-20 Annual Report Analysis (Annual Result Update)
Dec 7, 2020 | Updated on Dec 7, 2020Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.
Nazara Technologies IPO: Should You Apply? (IPO)
Mar 17, 2021Should you bet on this gaming company backed by ace investor Rakesh Jhunjhunwala?
CIPLA 2019-20 Annual Report Analysis (Annual Result Update)
Nov 4, 2020 | Updated on Nov 4, 2020Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)
Apr 6, 2021Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
An India Revival Stock I'm Bullish On... (Profit Hunter)
Apr 9, 2021This could take India to the position of 3rd largest economy.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
A Unique Sector for Short-Term Profits (Fast Profits Daily)
Apr 12, 2021This ignored sector could deliver big short-term profits.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
INDOCO REMEDIES SHARE PRICE
Apr 16, 2021 (Close)
TRACK INDOCO REMEDIES
- Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON INDOCO REMEDIES
INDOCO REMEDIES 8-QTR ANALYSIS
COMPARE INDOCO REMEDIES WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.